Makena Panel Vote Adversely Influenced By Framing Of Withdrawal Question, Covis Says
Executive Summary
‘Ad hoc narrowing’ of the final voting question by hearing officer Celia Witten prevented adcomm members from voting on Covis’ proposal to restrict the preterm birth prevention drug's indication while further study was conducted, company says.
You may also be interested in...
Intarcia’s Fight To Win ITCA 650 Approval: Former Employees Object To FDA AdComm Presentations
In another case of criticism after an adcomm, three former Intarcia employees, including the key developer of the ITCA 650 device, contend agency made ‘erroneous statements’ about performance and manufacturing to the advisory committee that voted unanimously against the type 2 diabetes treatment.
Makena Enforcement Discretion, Compounding Still In Limbo Post Long-Awaited Withdrawal
US FDA Commissioner and Chief Scientist call for immediate withdrawal of the preterm birth prevention drug and generic versions but defer to the Center for Drug Evaluation and Research on how to implement key lingering details.
End Of An Accelerated Approval Odyssey: Covis Agrees To Withdraw Makena But Seeks 21-Week ‘Wind-Down’
Covis says it respects advisory committee vote at October public hearing favoring withdrawal; proposal comes four years after failure of the PROLONG confirmatory trial to confirm clinical benefit in preventing preterm birth.